QOP
LFCR icon

Quinn Opportunity Partners’s Lifecore Biomedical LFCR Stock Holding History

Quinn Opportunity Partners’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Hold
453,495
– – 0.11% 162
2026
Q1 		$1.69M Buy
453,495
+210,825
+87% +$1.46M 0.09% 175
2025
Q4 		$1.99M Buy
242,670
+58,189
+32% +$430K 0.08% 177
2025
Q3 		$1.36M Sell
184,481
-17,771
-9% -$134K 0.1% 163
2025
Q2 		$1.64M Buy
202,252
+48,806
+32% +$329K 0.14% 148
2025
Q1 		$1.08M Buy
153,446
+25,542
+20% +$159K 0.07% 205
2024
Q4 		$950K Hold
127,904
– – 0.06% 208
2024
Q3 		$631K Buy
127,904
+19,920
+18% +$104K 0.06% 177
2024
Q2 		$554K Buy
107,984
+13,171
+14% +$78K 0.06% 167
2024
Q1 		$503K Buy
+94,813
New +$678K 0.06% 171

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Quinn Opportunity Partners's LFCR Position: Q2 2026 in Review

Quinn Opportunity Partners held its Lifecore Biomedical (LFCR) position steady in Q2 2026 at 453,495 shares worth $2.38M. The position accounts for 0.11% of the portfolio, ranked #162.

Quinn Opportunity Partners first reported a position in LFCR in Q1 2024 and has held it in 10 quarters since. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Quinn Opportunity Partners held 453,495 shares of Lifecore Biomedical worth $2.38M as of Q2 2026.
  • Quinn Opportunity Partners left its Lifecore Biomedical share count unchanged in Q2 2026.
  • Lifecore Biomedical made up 0.11% of Quinn Opportunity Partners's portfolio in Q2 2026, its #162 holding.
  • Quinn Opportunity Partners first reported a position in Lifecore Biomedical in Q1 2024 and has held it in 10 quarters since.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.